Bio-Rad reports Q4 adjusted EPS $2.51, consensus $2.70

Reports Q4 revenue $693.2M, consensus $687.71M. Norman Schwartz, Bio-Rad’s (BIO) Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market adoption of our expanded ddPCR product portfolio. As we enter 2026, we remain committed to improving overall performance.”